JP2011511810A - インドール化合物およびその使用方法 - Google Patents

インドール化合物およびその使用方法 Download PDF

Info

Publication number
JP2011511810A
JP2011511810A JP2010546107A JP2010546107A JP2011511810A JP 2011511810 A JP2011511810 A JP 2011511810A JP 2010546107 A JP2010546107 A JP 2010546107A JP 2010546107 A JP2010546107 A JP 2010546107A JP 2011511810 A JP2011511810 A JP 2011511810A
Authority
JP
Japan
Prior art keywords
alkyl
compound
substituents
amino
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010546107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511810A5 (cg-RX-API-DMAC7.html
Inventor
ハワード ピー. サード,
イーリン チャン,
チエ リー,
ルイス シャスター,
ブライアン ロス,
ニールズ イェンセン,
Original Assignee
オーガニクス インコーポレイテッド
タフツ ユニバーシティー
ユニバーシティー オブ ノース カロライナ, チャペル ヒル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーガニクス インコーポレイテッド, タフツ ユニバーシティー, ユニバーシティー オブ ノース カロライナ, チャペル ヒル filed Critical オーガニクス インコーポレイテッド
Publication of JP2011511810A publication Critical patent/JP2011511810A/ja
Publication of JP2011511810A5 publication Critical patent/JP2011511810A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2010546107A 2008-02-11 2009-02-11 インドール化合物およびその使用方法 Withdrawn JP2011511810A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2782508P 2008-02-11 2008-02-11
PCT/US2009/033822 WO2009102805A1 (en) 2008-02-11 2009-02-11 Indole compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2011511810A true JP2011511810A (ja) 2011-04-14
JP2011511810A5 JP2011511810A5 (cg-RX-API-DMAC7.html) 2012-04-05

Family

ID=40445507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010546107A Withdrawn JP2011511810A (ja) 2008-02-11 2009-02-11 インドール化合物およびその使用方法

Country Status (6)

Country Link
US (1) US20090318527A1 (cg-RX-API-DMAC7.html)
EP (1) EP2254865A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011511810A (cg-RX-API-DMAC7.html)
AU (1) AU2009214724A1 (cg-RX-API-DMAC7.html)
CA (1) CA2715282A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009102805A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525036A (ja) * 2019-03-07 2022-05-11 アーバーメンティス・エルエルシー 非サイケデリック/精神異常発現性の投与量及び製剤で投与される神経可塑性作用を有する物質を含む組成物並びに使用方法
JP2023513680A (ja) * 2020-02-04 2023-04-03 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
JP2024520485A (ja) * 2021-05-26 2024-05-24 ブライト マインズ バイオサイエンスィズ インコーポレイテッド 複素環式化合物及びその調製方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047032A2 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
WO2011014128A1 (en) * 2009-07-30 2011-02-03 National University Of Singapore Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
US8912220B2 (en) 2009-08-10 2014-12-16 Galenea Pharmaceuticals Compounds and methods of use thereof
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3519816A4 (en) * 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
US20230021957A1 (en) * 2019-12-04 2023-01-26 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
CA3201913A1 (en) 2020-12-09 2022-06-16 Andrew R. Chadeayne Dialkyl trytamines and their therapeutic uses
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
CA3244229A1 (en) * 2021-12-24 2023-06-29 Psylo Pty Ltd COMPOUNDS
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
CA3261749A1 (en) * 2022-07-15 2024-01-18 Caamtech, Inc. TRYPTAMINE DERIVATIVES
AU2023323907A1 (en) * 2022-08-11 2025-02-20 Gilgamesh Pharmaceuticals, Inc. Tryptamines and methods of treating mood disorders
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
EP4735441A1 (en) 2023-06-28 2026-05-06 Psylo Pty Ltd Pyrrolopyridine compounds for the treatment of mental illnesses
JP2026524104A (ja) 2023-06-28 2026-07-17 サイロ プロプリエタリー リミテッド 化合物
WO2025099725A1 (en) 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566056T3 (es) * 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
WO2006047032A2 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525036A (ja) * 2019-03-07 2022-05-11 アーバーメンティス・エルエルシー 非サイケデリック/精神異常発現性の投与量及び製剤で投与される神経可塑性作用を有する物質を含む組成物並びに使用方法
JP7679304B2 (ja) 2019-03-07 2025-05-19 アーバーメンティス・エルエルシー 非サイケデリック/精神異常発現性の投与量及び製剤で投与される神経可塑性作用を有する物質を含む組成物並びに使用方法
JP2023513680A (ja) * 2020-02-04 2023-04-03 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
JP2023513679A (ja) * 2020-02-04 2023-04-03 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
JP2024054193A (ja) * 2020-02-04 2024-04-16 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
JP2024520485A (ja) * 2021-05-26 2024-05-24 ブライト マインズ バイオサイエンスィズ インコーポレイテッド 複素環式化合物及びその調製方法

Also Published As

Publication number Publication date
AU2009214724A1 (en) 2009-08-20
CA2715282A1 (en) 2009-08-20
WO2009102805A1 (en) 2009-08-20
US20090318527A1 (en) 2009-12-24
EP2254865A1 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
CN113784962B (zh) 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
US20090318527A1 (en) Indole compounds and methods of use thereof
US8071786B2 (en) Indole compounds useful as serotonin selective agents
JP4094950B2 (ja) インドール誘導体および5−ht2bおよび5−ht2c受容体リガンドとしてのそれらの使用
CA2769474C (fr) Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
CN115403570B (zh) μ-阿片受体激动剂及其制备方法和在医药领域的应用
FR2903101A1 (fr) Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPH08109169A (ja) 非ペプチドタキキニン受容体拮抗物質
TW200836743A (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
US20150045442A1 (en) Novel melatonin ligands having antidepressant activity as well as sleep inducing properties
CA2722258C (fr) N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
EP0737670B1 (fr) Amides tricycliques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
CN110446495A (zh) 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
EA015974B1 (ru) Производные пирролизина, индолизина и хинолизина, их получение и их применение в терапии
CA3104808A1 (en) Lactate enhancing compounds and uses thereof
EP0994102B1 (fr) Dérivés cycliques à chaíne cycloalkylénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JP2014532629A (ja) Kcnqカリウムチャネル作動薬として使用できる新規な化合物、その製造方法および用途
AU2008315309A1 (en) Amino arylsulfonamide compounds and their use as 5-HT6 ligands
WO2009022062A1 (fr) Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2009022063A2 (fr) Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HK40065557A (en) Azepino-indoles and other heterocycles for treating brain disorders
WO2005012282A1 (fr) Nouveaux derives du benzothiofene 2-thiosubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120210

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130620

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20130702